Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intersectin-1 is a multi-domain, cytoplasmic membrane-associated scaffold protein encoded by the ITSN1 gene. It acts as an adaptor linking endocytic membrane trafficking with the actin cytoskeleton and coordinates the formation of clathrin-coated vesicles, synaptic vesicle recycling, and various signal transduction pathways[1][3][7]. ITSN1 exists in long (ITSN1-L) and short (ITSN1-S) isoforms due to alternative splicing, with some isoforms serving as guanine nucleotide exchange factors (GEFs) for small GTPases like Cdc42[2][5]. The protein is involved in neuronal development, dendritic spine morphology, and interacts with multiple partners such as dynamin, CDC42, EPS15, and endophilin, integrating endocytic processes with actin cytoskeleton dynamics and signaling[1][3][4][5][7]. Misregulation or mutation of ITSN1 has been linked to cancer progression and some neurodegenerative diseases, including Alzheimer's disease and Down syndrome[3][5]. There are currently no drugs directly targeting Intersectin-1, and it is not considered a traditional therapeutic receptor, enzyme, or transporter.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intersectin-1 (ITSN1).